静脉注射人骨髓CD133+细胞移植治疗中风大鼠的局限性。
Limitations of intravenous human bone marrow CD133+ cell grafts in stroke rats.
作者信息
Borlongan Cesar V, Evans Andrew, Yu Guolong, Hess David C
机构信息
Department of Neurology, BI-3080, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912-3200, USA.
出版信息
Brain Res. 2005 Jun 28;1048(1-2):116-22. doi: 10.1016/j.brainres.2005.04.087.
We examined the effects of timing and routes of transplantation on survival and functional benefits of human bone-marrow-derived CD133+ cells in experimentally stroke Sprague-Dawley rats. At day 7 post-stroke, both immediate and delayed intracerebral transplantation resulted in similar graft survival (7%) that was localized within the original transplant site and reduction of motor (27%) and neurological (40%) deficits. In contrast, graft survival (0.01-0.04%) was only detected in delayed intravenous transplantation, characterized by cell migration throughout the ipsilateral stroke hemisphere. Behavioral improvement, however, was limited to neurological response and only apparent in immediate intravenous transplantation. Reduction of cerebral infarct (25%) was only noted in intracerebral transplantation. Intravenous transplantation requires optimization for improved therapeutic outcome of CD133+ cell grafts in stroke.
我们研究了移植时间和途径对实验性中风的斯普拉格-道利大鼠中人骨髓源性CD133+细胞存活及功能益处的影响。中风后第7天，脑内即刻移植和延迟移植均导致相似的移植物存活率（7%），移植物局限于原移植部位，运动功能缺损（27%）和神经功能缺损（40%）减轻。相比之下，仅在延迟静脉移植中检测到移植物存活（0.01 - 0.04%），其特征是细胞迁移至同侧中风半球。然而，行为改善仅限于神经反应，且仅在即刻静脉移植中明显。仅在脑内移植中观察到脑梗死面积减小（25%）。静脉移植需要优化，以改善中风中CD133+细胞移植的治疗效果。
Zotero 插件